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Type	  2	  Diabetes	  Mellitus	   is	   associated	  with	  elevated	  blood	  glucose	  
level,	   abnormal	   abdominal	   fat	   deposition,	   insulin	   resistance	   and	   a	  
number	   of	   complications	   including	   embryopathy,	   cardiovascular	  
diseases,	   nephropathy,	   neuropathy,	   microangiopathy	   and	  
retinopathy.	  Complications	  extending	  to	  the	  central	  nervous	  system	  
may	  have	  a	  deteriorating	  effect	  on	  mental	  health	  including	  a	  decline	  
in	  cognitive	  functioning.	  This	  could	  be	  a	  reason	  for	  depression,	   lack	  
of	   compliance	   towards	   medication/treatment,	   and	   the	   inability	   of	  
patients	   to	   meet	   the	   day-­‐to-­‐day	   management	   demands	   of	   the	  
disease.	  Due	  to	  the	  high	  metabolic	  demand	  for	  energy	  in	  the	  brain,	  
perturbations	  in	  glucose	  metabolism	  can	  noticeably	  impact	  cognitive	  
performance.	   This	   review	   discusses	   and	   enlightens	   on	   the	   factors	  
contributing	   to	   cognitive	   impairment	   in	   Type	   2	   Diabetes	   Mellitus.	  	  
An	   understanding	   of	   the	  mechanisms	   of	   diabetes-­‐related	   cognitive	  
impairment	   and	   the	   resulting	   behaviors	   of	   patients	   can	   help	  
healthcare	   professionals	   implement	   treatments	   to	   significantly	  
improve	  health	  status	  and	  quality	  of	  life	  of	  patients	  with	  diabetes.	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Diabetes	   mellitus	   remains	   a	   major	   global	   health	   problem	  
impacted	   by	   genetic	   risk	   propensity.	   Whilst	   this	   makes	   it	  
largely	  unpreventable,	  there	  exist	  preventive	  measures,	  which	  
reduce	   the	   onset	   of	   the	   disease	   and	   the	   extent	   of	   the	  
progression	   of	   associated	   complications	   in	   patients	   with	  
diabetes1.	  Type	  2	  Diabetes	  is	  associated	  with	  the	  elevation	  of	  
blood	   glucose	   level,	   abnormal	   abdominal	   fat	   deposition,	  
insulin	   resistance	   and	   a	   number	   of	   complications	   including	  
embryopathy,	   cardiovascular	   diseases,	   nephropathy,	  
neuropathy,	  microangiopathy	  and	  retinopathy2-­‐4.	  
Complications	   of	   diabetes	   extending	   to	   the	   central	   nervous	  
system	   lead	   to	   a	   range	   of	   alterations	   in	   brain	   functioning5,6.	  
Diabetes-­‐related	   cognitive	   impairment	   is	   a	   likely	   cause	   of	  
depression	  and	  interference	  with	  a	  number	  of	  processes	  such	  
as	   patient’s	   non-­‐adherence	   to	   medication/treatment,	   being	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noncompliant	   (for	   example,	   patient’s	  
likelihood	   to	   participate	   in	   exercise	  
programs	   and	   tendency	   to	   stay	   on	  
appropriate	   diets)	   and	   inability	   to	   do	  
primary	   self-­‐care7,8.	   While	   the	   need	   to	  
address	   why	   increasing	   numbers	   of	  
people	   are	   suffering	   from	   diabetes	  
abounds,	   it	   is	   also	   important	   to	   look	   into	  
ways	  to	  help	  patients	  meet	  the	  day-­‐to-­‐day	  
challenges	   of	   the	   disease,	   which	   may	   be	  
derived	   through	   development	   of	   new	  
treatments	   and	  management	   strategies9.	  	  
An	   assessment	   of	   the	   levels	   of	   cognitive	  
impairment	   in	  patients	  with	  diabetes	  will	  
help	   to	   understand	   the	   behavior	   of	  
patients	   towards	   medication,	   treatment,	  
nutrition	  and	  to	  their	  lifestyle	  as	  a	  whole.	  
Our	  research	  to	  define	  cognitive	  functions	  
in	  Type	  2	  Diabetes	  patients	   is	   focused	  on	  
the	   effects	   of	   dietary	   functional	  
supplements	   like	   chocolate,	   fermented	  
papaya	   preparation	   and	   tea	   (green	   and	  
black	   tea)	   on	   cognitive	   performance	   and	  
health	   management	   of	   the	   prediabetic,	  
diabetic	  and	  ischaemic	  heart	  patients10-­‐12.	  
The	   outcome	   can	   be	   benchmarked	   with	  
the	  assessment	  of	  the	  effects	  of	  available	  
therapeutic	   drugs	   on	   cognition	  
functioning	   as	   well	   as	   the	   assessment	   of	  
the	  genetic	  relationship	  between	  diabetes	  
and	   cognitive	   deficits13.	   The	   remarks	   of	  
Perrin	   et	   al14,	   that	   “People	  with	  diabetes	  
and	  peripheral	  neuropathy	  have	  different	  
illness	   schemata	   that	   may	   influence	  
health-­‐related	  behavior.	   Education	  aimed	  
at	  improving	  foot-­‐care	  behavior	  and	  foot-­‐
health	   outcomes	   should	   be	   tailored	   to	  
specific	   illness	   schemata	   related	   to	  
peripheral	   neuropathy”,	   is	   of	   worthwhile	  
interest	  for	  readers	  to	  refer	  to	  the	  context	  
of	   the	   paper.	   In	   the	   study	   of	   Le	   Floch	   et	  
al15,	  it	  was	  found	  that	  in	  people	  with	  Type	  
2	   Diabetes	   aged	   70	   years	   and	   older,	  
retinopathy,	   nephropathy	   and	   peripheral	  
neuropathy	   were	   associated	   with	  
impaired	  geriatric	   scale	   scores.	  The	   study	  
highlights	   the	   benefits	   of	   systematic	  
assessment	   of	   cognition,	   autonomy,	  
nutritional	   status	   and	   mood	   using	  
geriatric	   scales	   in	   elderly	   people	   with	  
diabetes.	   The	   prevention	   and	  
management/treatment	   of	   diabetes-­‐
related	  cognitive	  deficits	  will	  not	  only	  lead	  
to	   a	   better	   health	   status	   of	   patients	   but	  
will	   ultimately	   improve	   their	   quality	   of	  
life.	  
	  
FACTORS	   CONTRIBUTING	   TO	  
COGNITIVE	  IMPAIRMENT	  
In	   the	   metabolic	   integrity,	   aging	   process	  
and	   perturbations	   caused	   by	   problems	  
such	   as	   insulin	   resistance16,	   chronic	  
inflammation17,	   oxidative	   stress18,	  
declining	   hormone	   levels19	   and	  
endothelial	   dysfunction20,	   result	   in	  
physical	   deterioration	   of	   the	   brain	   and	  
subsequent	  cognitive	  decline.	  The	   factors	  
are	   discussed	   with	   emphasis	   on	   aging,	  
insulin	  resistance,	  inflammation,	  oxidative	  
stress	  and	  hormonal	  imbalance.	  
	  
Aging	  
Aging	  is	  a	  gradual	  and	  complex	  process	  in	  
which	  cells,	  tissues,	  organs	  and	  the	  whole	  
organism	   itself	   deteriorates	   in	   a	  
progressive	  and	   irreversible	  manner	   that,	  
in	   the	   majority	   of	   cases,	   implies	  
pathological	   conditions	   that	   affect	   the	  
individual’s	   quality	   of	   life.	   The	   process	  
profoundly	   impacts	   the	   brain	   and	   causes	  
deterioration	   of	   neuronal	   and	  
mitochondrial	  membranes,	  which	  leads	  to	  
the	   loss	  of	   cellular	   integrity	  and	   impaired	  
neuronal	   function.	   	   Diabetes-­‐related	  
complications	   lead	   to	  acute	  alterations	   in	  
mental	   status	   due	   to	   poor	   metabolic	  
control	  as	  well	  as	  greater	  rates	  of	  decline	  
of	   cognitive	   functioning	   with	   age21,22,	  
higher	   prevalence	   of	   depression23	   and	  
increased	   risk	   of	   Alzheimer’s	   disease24,25.	  
Alzheimer’s	  disease	   (AD),	   is	   characterized	  
by	   dementia	   that	   typically	   begins	   with	  
subtle	   and	   poorly	   recognized	   failure	   of	  
memory	  and	  slowly	  becomes	  more	  severe	  
and,	   eventually,	   incapacitating.	   The	  
clinical	  diagnosis	  of	  AD	  is	  characterized	  by	  
slow	   progressive	   dementia	   and	   gross	  
cerebral	  cortical	  atrophy.	  The	  age-­‐related	  
declines	   in	   neurotransmitter	   synthesis	  
and	   signaling,	   coupled	  with	   reductions	   in	  
synaptic	   density	   and	   plasticity	  
(adaptability),	  and	  loss	  of	  as	  much	  as	  50%	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of	   the	   length	   of	   myelinated	   axons	   make	  
the	   brain	   increasingly	   less	   efficient	   with	  
aging.	   As	   noted	   by	   Riddle26,	   “The	   basic	  
cognitive	   functions	  most	   affected	   by	   age	  
are	   attention	   and	   memory.	   Neither	   of	  
these	  are	  unitary	  functions,	  however,	  and	  
some	   aspects	   of	   attention	   and	   memory	  
hold	   up	  well	  with	   age	  while	   others	   show	  
significant	   declines”.	   Perception	   (often	  
considered	   to	  be	  a	  precognitive	   function)	  
also	  shows	  significant	  age-­‐related	  declines	  
attributable	   mainly	   to	   declining	   sensory	  
capacities.	   Thus,	   deficits	   at	   these	   early	  
processing	   stages	   could	   affect	   cognitive	  
functions	   later	   in	   the	   processing	   stream.	  
Higher-­‐level	   cognitive	   functions	   such	   as	  
language	   processing	   and	   decision-­‐making	  
may	  also	  be	  affected	  by	  age.	   These	   tasks	  
naturally	   rely	   on	   more	   basic	   cognitive	  
functions	   and	  will	   generally	   show	  deficits	  
to	   the	   extent	   that	   those	   fundamental	  
processes	   are	   impaired.	   Herein	   lies	   the	  
premise	   of	   the	   treatise	   pursuant	   of	  
creating	   an	   understanding	   of	   how	  
patients	   can	   manage	   their	   lifestyle	   to	  




Due	   to	   the	   high	   metabolic	   demand	   for	  
energy	  in	  the	  brain,	  small	  perturbations	  in	  
glucose	  metabolism	  can	  noticeably	  impact	  
cognitive	  performance.	  Diabetes	  has	  been	  
linked	   with	   lower	   levels	   of	   neuronal	  
growth	   factors27,	   decreased	   brain	  
volume28	  and	  higher	  incidence	  of	  all	  types	  
of	  dementia29.	   In	  a	  study	  by	  Baker	  et	  al30,	  
it	   was	   shown	   that	   when	   a	  memorization	  
task	   was	   assigned	   to	   test	   the	   recalling	  
ability	   of	   diabetics	   and	   pre-­‐diabetics	  
against	  a	  control	  population,	  subjects	  with	  
healthy	  glucose	  metabolism	   remembered	  
more	   words	   and	   interestingly,	  
Fludeoxyglucose-­‐Positron	   Emission	  
Tomography	   (FDG-­‐PET)	   scans	   of	   those	  
with	   pre-­‐diabetes/diabetes	   resembled	  
brain	   scans	   of	   AD	   patients.	   The	   paper	   of	  
Alagiakirshnan	   et	   al13	   addressed	   the	  
context	   of	   antidiabetic	   drugs	   and	   their	  
potential	   role	   in	   treating	   mild	   cognitive	  
impairment	   and	   AD	   and	   concluded	   that	  
“while	   it	   remains	   unclear	   whether	  
management	   of	   diabetes	   will	   reduce	   the	  
incidence	   of	   mild	   cognitive	   impairment	  
(MCI)	   and	   AD,	   emerging	   evidence	  
suggests	   that	   diabetes	   therapies	   may	  
improve	   cognitive	   function”.	   As	   evident	  
from	   the	   forgoing	   discussions,	   the	  
incidence	   of	   both	   diabetes	   mellitus	   and	  
dementia	   increases	   with	   aging	   and	   the	  
incidence	   of	   dementia	   are	   higher	   in	  
people	   with	   diabetes.	   Although	   diabetes	  
mellitus	  seems	  to	  be	  an	   independent	  risk	  
factor	   for	   MCI	   and	   AD,	   evidence	   is	  
pointing	   to	   the	   potential	   that	   insulin	  
affects	   central	   nervous	   system	   functions	  
and	   hence	   can	   modulate	   cognitive	  
functions.	   Impaired	   insulin	   signaling	   and	  
insulin	  resistance	  in	  the	  brain	  may	  play	  an	  
important	   role	   in	   the	   pathogenesis	   of	  
AD31.	   The	   exact	   mechanism	   by	   which	  
insulin	   improves	   cognitive	   function	   is	  
unknown	   but	   molecular	   interactions	  
between	  insulin	  signaling,	  amyloid	  beta	  (a	  
protein	  involved	  in	  the	  formation	  of	  senile	  
plaques	   that	   can	   lead	   to	   AD)	   and	   tau	  
phosphorylation	   are	   widely	   reported.	   It	  
has	   been	   shown	   that	   amyloid	   can	   inhibit	  
insulin	  signaling.	  Amyloid	  beta	  expression	  
decreases	   AKT	   phosphorylation	   and	  
disrupts	   insulin	   signal	   transmission,	   likely	  
by	  inhibiting	  the	  interaction	  between	  AKT	  
and	   PDK1,	   and	   amyloid	   beta	   can	   also	  
directly	  compete	  with	   insulin	   to	  decrease	  
its	   binding	   to	   insulin	   receptors.	   The	  
interplay	   between	   insulin	   signaling,	  
amyloid	   beta,	   and	   tau	   phosphorylation	  
will	   likely	   contribute	   to	   any	   long-­‐term	  
benefits	  of	  insulin31.	  
	  
Inflammation	  
The	   inflammatory	   process	   in	   the	   brain	   is	  
unique	   in	   that	   the	   blood-­‐brain	   barrier	  
(tight	   layer	   of	   endothelial	   cells	   that	  
separates	  the	  brain	  from	  regular	  systemic	  
circulation),	   during	   healthy	   conditions,	  
prevents	   the	   infiltration	   of	   inflammatory	  
agents	   and	   allows	   only	   select	   nutrients	  
and	   small	   molecules	   into	   the	   central	  
nervous	  system	  (CNS)32.	  However,	  chronic	  
systemic	   inflammation	   induced	  by	  stimuli	  
such	   as	   cigarette	   smoking,	   obesity,	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disrupted	  sleep	  patterns	  and	  poor	  dietary	  
habits	   compromises	   the	   integrity	   of	   the	  
blood-­‐brain	   barrier,	   allowing	   irritants	   to	  
enter	   the	   brain	   and	   stimulate	   the	  
production	   of	   inflammatory	   cytokines,	  
such	   as	   IL-­‐1β,	   IL-­‐6	   and	   IL-­‐18.	   Inside	   the	  
CNS,	  these	  cytokines	  impair	  neurogenesis,	  
the	   process	   by	   which	   new	   neurons	   are	  
generated33,34.	   Aside	   from	   inhibiting	  
neurogenesis,	   some	   inflammatory	  
cytokines,	   such	   as	   IL-­‐1β,	   IL-­‐6	   and	   TNF-­‐α	  
damage	   and	   destroy	   existing	   neurons35.	  
Yaffe	   et	   al36	   assessed	   the	   potential	  
contribution	   of	  metabolic	   syndrome	   as	   a	  
risk	  factor	  for	  cognitive	  decline	  and	  if	  this	  
can	   be	   modified	   by	   inflammation.	   This	  
important	   study	   sought	   to	   establish	   if	  
biomarkers	   of	   inflammation	   could	   be	  
linked	   with	   cognitive	   impairment.	   The	   5-­‐
year	   prospective	   observational	   study	  
looked	  at	  the	  association	  of	  the	  metabolic	  
syndrome	  and	  high	  inflammation	  (defined	  
as	   above	   median	   serum	   level	   of	  
interleukin	  6	  and	  C-­‐reactive	  protein)	  with	  
changes	  in	  cognition.	  Metabolic	  syndrome	  
may	  contribute	  to	  cognitive	  impairment	  in	  
elders,	   but	   primarily	   in	   those	   with	   high	  
level	   of	   inflammation.	   Indeed,	   serum	  
markers	   of	   inflammation,	   especially	   IL-­‐6	  
and	   CRP,	   are	   prospectively	   associated	  
with	   cognitive	   decline	   in	  well-­‐functioning	  
elders36.	   This	   contributes	   to	  defining	   that	  
inflammation	   contributes	   to	   cognitive	  
decline	  in	  the	  elderly.	  
	  
Oxidative	  Stress	  
The	   brain	   is	   particularly	   prone	   to	   free	  
radical	   attacks	   owing	   to	   its	   relatively	   low	  
antioxidant	   content,	   a	   considerable	  
amount	   of	   polyunsaturated	   fatty	   acid	  
chains	   in	   the	   neuronal	   membrane	   lipids	  
and	   its	   high	   oxygen	   consumption	   rate37.	  
The	   pathological	   hallmarks	   of	   AD	   include	  
high	   levels	  of	  oxidative	  stress	   (defined	  by	  
the	   status	   when	   endogenous	   antioxidant	  
protection	   is	   overwhelmed	   by	   increased	  
level	   of	   oxidants),	   intra-­‐neuronal	   amyloid	  
beta	   peptide	   accumulation,	   extracellular	  
senile	  amyloid	  plaques,	  intraneuronal	  and	  
extraneuronal	   neurofibrillary	   tangles	  
made	   of	   hyper-­‐phosphorylated	   tau,	   loss	  
of	   synapses,	   loss	   of	   neurons	   and	   neuritic	  
degeneration	   and	   gliosis.	   This	   pathology	  
culminates	   in	  clinical	   signs	  predominantly	  
associated	   with	   impaired	   cognitive	  
processes.	   The	   underlying	   cause	   and	  
molecular	   inter-­‐relationship	   between	  
these	   pathological	   entities	   and	   a	   full	  
understanding	   of	   the	   cell	   signaling	  
pathways	   relevant	   to	   neuronal	  
death/survival	   is	   critical	   for	   informed	  
discovery	   of	   compounds	   to	   combat	   AD.	  
One	  of	  the	  major	  role	  of	  the	  mitochondria	  
in	   brain	   metabolism	   is	   the	   provision	   of	  
ATP	   via	   oxidative	   phosphorylation	   in	  
order	   to	   drive	   energy-­‐dependent	  
processes38	  (Figure	  1).	  Amyloid-­‐β	  (A-­‐beta)	  
increases	   the	   level	   of	   mitochondrial	  
reactive	  oxygen	  species	  (ROS)	  production.	  
The	   sources	   of	   ROS-­‐mediated	   damage	  
appear	   to	   be	   multi-­‐faceted	   in	   AD,	   with	  
interactions	   between	   abnormal	  
mitochondria,	   redox	   transition	   metals,	  
and	   other	   factors.	   Amyloid	   precursor	  
protein	   (APP)	   is	   found	   in	   mitochondria	  
and	   may	   accumulate	   exclusively	   in	   the	  
protein	   import	   channels	   of	   mitochondria	  
of	   human	   AD	   brains	   but	   not	   in	   age-­‐
matched	   controls.	   The	   levels	   of	  
translocationally	   arrested	   mitochondrial	  
APP	  directly	   correlate	  with	  mitochondrial	  
dysfunction	   and	   severity	   of	   the	   disease.	  
Neuropathologic	   findings	   of	   β-­‐amyloid	  
plaques	   and	   intraneuronal	   neurofibrillary	  
tangles	   remain	   the	   gold	   standard	   for	  
diagnosis	   of	   Alzheimer’s	   disease.	   The	  
association	  of	  the	  APOE	  e4	  allele	  with	  AD	  
is	   significant;	   however,	   APOE	   genotyping	  
is	   neither	   fully	   specific	   nor	   sensitive.	  
While	   APOE	   genotyping	   may	   have	   an	  
adjunct	   role	   in	   the	   diagnosis	   of	   AD	   in	  
symptomatic	  individuals,	  it	  may	  have	  little	  
role	   at	   this	   time	   in	   predictive	   testing	   of	  
asymptomatic	   individuals39.	   Aruoma	   et	  
al40	   investigated	   the	   potential	   cytotoxic	  
effect	   of	   aggregated	   A-­‐beta	   (1-­‐42)	   to	  
neurons	   that	   express	   several	   classical	  
neurotransmitters	   (such	   as	   acetylcholine,	  
catecholamines,	   serotonin	   and	   gamma-­‐
amino	  butyric	  acid.	  Aggregated	  A-­‐beta	  (1-­‐
42)	   has	   a	   multisystem	   cytotoxic	   effect	  
causing	   non-­‐specific	   reduction	   in	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immunoreactivity,	   dysfunction	   or	   loss	   of	  
retinal	   nerve	   cells.	   Using	  
immunocytochemistry,	  TUNEL	  staining	  for	  
apoptosis	   and	   measurement	   of	   cell	  
density	   as	   well	   as	   retinal	   surface	   area,	   a	  
differential	  acute	  and/or	  chronic	  effect	  of	  
A-­‐beta	   on	   choline	   acetyl	   transferase,	  
gamma-­‐aminobutyric	   acid	   and	   5-­‐
tryptamine	   hydroxylase	   systems,	   was	  
observed	  with	   the	   increasing	   time	  course	  
of	  6h	  to	  5	  months	  and	  a	  bilateral/systemic	  
effect.	   In	   contrast,	   the	   overall	   pattern	   of	  
catecholaminergic	   system,	  as	   revealed	  by	  
tyrosine	   hydroxylase	   immunoreactivity	   of	  
the	   retina,	   appears	   to	   have	   remained	  
relatively	   unaffected	   by	   A-­‐beta	   (however	  
this	   may	   reflect	   neuronal	   loss	   due	   to	  
reduction	   in	   the	   retinal	   surface).	   This	   in	  
vivo	  evidence	   in	  a	  CNS	  model	   shows	   that	  
not	   only	   all	   major	   neurotransmitter	  
systems	   are	   differentially	   affected	   by	   A-­‐
beta	   aggregates,	   but	   the	   effect	  may	   vary	  
from	   one	   transmitter	   system	   to	   another	  
under	   the	   same	   experimental	   conditions	  




Figure	  1.	  Mitochondrial	  biology	  in	  Alzheimer’s	  disease	  pathogenesis	  depicting	  the	  potential	  role	  of	  
Amyloid-­‐β	   (Aβ).	   Mitochondria	   play	   a	   critical	   role	   in	   brain	   metabolism,	   their	   major	   role	   being	   the	  
provision	  of	  ATP	  via	  oxidative	  phosphorylation	  to	  drive	  energy-­‐dependent	  processes.	  Loss	  of	  complex	  
IV	   activity	   represents	   key	   cytopathologies	   in	   Alzheimer’s	   disease.	   Oxidative	   damage	   contributes	   to	  
Alzheimer’s	  disease	  pathogenesis.	  Amyloid-­‐β	   increases	  mitochondrial	   reactive	  oxygen	   species	   (ROS)	  
production.	  The	  sources	  of	  ROS-­‐mediated	  damage	  appear	  to	  be	  multi-­‐faceted	  in	  Alzheimer’s	  disease,	  
with	   interactions	   between	   abnormal	   mitochondria,	   redox	   transition	   metals,	   and	   other	   factors.	  
Through	  mitochondrial	  electron	  transport	  chain,	  a	  proton	  motive	   force	   is	  generated	  as	  a	  result	  of	  a	  
pH	   gradient	   and	   a	   transmembrane	   electrical	   potential	   (ΔΨ).	   ATP	   is	   synthesized	  when	   protons	   flow	  
back	   to	   the	  mitochondrial	  matrix.	   Hypo-­‐metabolism	  has	   long	   been	   implicated	   in	   the	   onset	   of	   both	  
familial	   and	   sporadic	   forms	   of	   AD.	   (From:	   Galindo	   FF,	   Ikuta	   I,	   Zhu	   X,	   Casadesus	   G,	   Jordán	   J.	  
Mitochondrial	   biology	   in	   Alzheimer’s	   disease	   pathogenesis.	   Journal	   of	   Neurochemistry.	   2010;	   114:	  
933–945.	  Copy	  right	  permission	  from	  John	  Wiley	  &	  Sons	  Inc.)	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Distributed	   throughout	   the	   brain	   are	  
steroid	  hormone	  receptors	  which	  function	  
to	   regulate	   the	   transcription	   of	   a	   vast	  
array	   of	   genes	   involved	   in	   cognition	   and	  
behaviour41.	   Cognitive	   performance	  
among	   older	   people	   is	   complex	   and	  
dependent	  on	  many	  factors	  and	  in	  spite	  of	  
the	   known	   effects	   of	   clinical	   thyroid	  
disorders	   on	   cognitive	   function,	   little	   is	  
known	   about	   the	   relationship	   between	  
thyroid	  hormone	  (TH)	  levels	  and	  cognitive	  
performance	   among	   older	   people	   with	  
levels	   of	   TH	  within	   the	   normal	   reference	  
range.	   Since	   thyroid	   hormone	  
concentrations	  change	  with	  age	  and	  since	  
cognitive	   decline	   is	   often	   concomitant	  
with	   aging,	   physiological	   changes	   in	  
thyroid	  function	  might	  be	  causally	  related	  
to	   changes	   in	   cognition	   during	   normal	  
aging42.	   When	   hormonal	   imbalances	   or	  
deficiencies	   disrupt	   receptor	   activation,	  
cognitive	   deficits	   and	   emotional	   turmoil	  
are	   the	   results.	   Feinkohl	   et	   al43	   in	   the	  
Edinburgh	   Type	   2	   Diabetes	   Study	  
conducted	   a	   cross-­‐sectional	   analysis	   of	  
1066	   men	   and	   women	   aged	   60-­‐75	   with	  
Type	  2	  Diabetes	  during	  which	   they	   found	  
that	  raised	  plasma	  NT-­‐proBNP	  was	  weakly	  
but	   statistically	   significantly	   associated	  
with	   poorer	   cognitive	   function	   and	  
depression.	   A	   further	   viewpoint	   on	   the	  
hormonal	   contribution	   to	   cognitive	  
function	  can	  be	  derived	  from	  the	  work	  of	  
Wijsman	   et	   al44.	   Subclinical	   thyroid	  
dysfunction	  has	  been	   implicated	  as	  a	   risk	  
factor	  for	  cognitive	  decline	  in	  old	  age,	  but	  
results	   are	   inconsistent.	   A	   prospective	  
longitudinal	   study	   of	   men	   and	   women	  
aged	   70-­‐82	   years	   with	   pre-­‐existing	  
vascular	   disease	   or	   more	   than	   one	   risk	  
factor	   to	   develop	   vascular	   disease	  
concluded	   that	   there	   was	   no	   consistent	  
association	   of	   subclinical	   hyper-­‐	   or	   hypo-­‐	  
thyroidism	   with	   altered	   cognitive	  
performance	   compared	   to	   euthyroid	  
participants	   on	   the	   individual	   cognitive	  
tests.	   Although	   there	   was	   no	   association	  
with	   rate	   of	   cognitive	   decline	   during	  
follow-­‐up,	   the	   consensus	   of	   opinion	   was	  
that	   a	   large	   randomized	   controlled	   trial	  
can	   provide	   definitive	   evidence	   for	   the	  
clinical	   and	   subclinical	   hypothyroidism	   as	  
well	   as	   overt	   hyperthyroidism	   in	   middle-­‐
aged	   and	   elderly	   adults	   thought	   to	   be	  
associated	   with	   decreased	   cognitive	  
functioning	   as	   memory,	   reaction	   time,	  
and	   visuo-­‐spatial	   organization.	  While	   this	  
type	   of	   study	  may	   also	   confirm	   or	   reject	  
the	   notion	   of	   causality	   between	   TSH	  
abnormalities	   and	   dementia43,44,	   the	  
potential	  of	  the	  disruption	  of	  the	  cerebral	  
white	   matter	   network	   being	   associated	  
with	   the	   slowing	   of	   information	  
processing	   speed	   in	   patients	  with	   Type	   2	  
Diabetes	   is	   widely	   debated45.	   Reijmer	   et	  
al46,	  have	  shown	  that	  patients	  with	  Type	  2	  
Diabetes	   have	   alterations	   in	   local	   and	  
global	  network	  properties	  compared	  with	  
controls.	   These	   structural	   network	  
abnormalities	   were	   related	   to	   slowing	   of	  
information	  processing	   speed	   in	  patients,	  
which	   may	   be	   independent	   of	  
cerebrovascular	   lesion	   load.	   Thus,	  
characterizing	   the	   brain	   as	   a	   network	  
using	   Diffusion	   Magnetic	   Resonance	  
Imaging	   and	   graph	   theory	   can	   provide	  
new	   insights	   into	   how	   abnormalities	   in	  
the	  white	  matter	  affect	  cognitive	  function	  
in	  patients	  with	  Diabetes.	  
	  
INSULIN	   AND	   ITS	   EFFECTS	   ON	   THE	  
BRAIN	  
Insulin	  plays	  a	  role	  in	  brain	  physiology	  and	  
disturbances	   of	   cerebral	   insulin	   signaling	  
and	  glucose	  homeostasis	  are	  implicated	  in	  
brain	  pathology47.	  	  When	  insulin’s	  signal	  is	  
ignored	  by	  cells,	  the	  brain	  may	  not	  get	  the	  
large	   amount	   of	   glucose	   energy	   it	   needs,	  
especially	  for	  memory.	  As	  a	  result,	  loss	  of	  
brain	   cells	   affects	   cognitive	   functioning.	  
Increased	   insulin	   concentrations	   also	  
appear	   to	   boost	   levels	   of	   beta-­‐amyloid.	  
Insulin	  and	  related	  growth	  proteins	  in	  the	  
brain	   are	   vital	   for	   cell	   survival	   and	   both	  
glucose	   and	   insulin	   appear	   to	   regulate	  
many	   brain	   functions,	   including	   learning	  
and	   memory4.	   Dysfunction	   of	   these	  
chemicals	   contributes	   to	   cognitive	  
deficits.	   Chronic	   episodes	   of	   high	   or	   low	  
levels	  of	  blood	  glucose	  may	  directly	  affect	  
insulin’s	   actions	   in	   the	   brain	   or	   damage	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brain	   cells,	   leading	   to	   cognitive	  
impairments.	   Diabetes	   mellitus	   is	  
associated	   with	   cognitive	   deficits,	   which	  
are	   paralleled	   by	   neurophysiological	   and	  
structural	  changes	  in	  the	  brain.	  MRI	  scans	  
are	   often	   performed	   to	   determine	  
structural	   changes	   at	   the	   level	   of	   the	  
brain.	   Brain	   cells	   have	   on	   their	   surface,	  
their	   own	   insulin-­‐receptors.	   In	   a	   study,	  
Kahn	   et	   al48	   found	   that	   reduction	   in	  
expression	   of	   major	   transcriptional	  
regulator	   of	   cholesterol	   metabolism,	  
SREBP-­‐2	  and	  its	  downstream	  genes	  in	  the	  
hypothalamus	   and	   other	   areas	   of	   the	  
brain,	   lead	   to	   reduction	   in	   brain	  
cholesterol	   synthesis	   and	   synaptosomal	  
cholesterol	  content.	  These	  changes	  are,	  at	  
least	   in	   part,	   due	   to	   direct	   effects	   of	  
insulin	  to	  regulate	  these	  genes	  in	  neurons	  
and	   glial	   cells	   and	   can	   be	   corrected	   by	  
intracerebroventricular	   injections	   of	  
insulin.	  
Cognitive	  functioning	  can	  be	  measured	   in	  
terms	   of	   intelligence,	  memory,	   language,	  
executive	  function	  and	  visual	  function	  and	  
assessment	   of	   these	   neuropsychological	  
processes	   can	   help	   to	   diagnose	   for	  
cognitive	  deficits.	  Each	  of	   these	   functions	  
is	   controlled	   by	   specific	   domains	   of	   the	  
brain.	   Diabetes	   affects	   the	   hippocampus,	  
which	  is	  involved	  in	  learning	  and	  memory.	  
In	   animal	   models	   of	   diabetes,	  
impairments	   of	   spatial	   learning	   occur	   in	  
association	   with	   distinct	   changes	   in	  
hippocampal	   synaptic	   plasticity.	   At	   the	  
molecular	   level,	   these	   impairments	  might	  
involve	   changes	   in	   glutamate-­‐receptor	  
subtypes,	   in	   second-­‐messenger	   systems	  
and	   in	   protein	   kinases.	   The	   pathogenesis	  
can	   be	   divided	   into	   three	   main	  
components:	   (1)	   direct	   ‘neurotoxic’	  
effects	   of	   hyperglycemia,	   including	  
increased	   polyol	   pathway	   flux,	   oxidative	  
stress,	   enhanced	   formation	   of	   advanced	  
glycated	   end-­‐products	   and	   disturbances	  
of	   Ca2+	   homeostasis;	   (2)	   vascular	  
changes,	   including	   alterations	   in	   cerebral	  
blood	  flow	  and	  angiopathy;	  (3)	  alterations	  
in	   neurotrophic	   support	   and	  
neuromodulatory	   changes	   related	   to	  
alterations	   in	   insulin	   and	   its	   receptors	   in	  
the	  brain.	   It	   is	   important	  to	  note	  that	  the	  
toxic	   effects	   of	   hyperglycemia	  might	   also	  
affect	  the	  vasculature,	  thus	  compromising	  
cerebral	   blood	   flow.	   Treatment	   with	  
insulin	   might	   therefore	   not	   only	   correct	  
hyperglycemia,	   but	   could	   also	   directly	  
affect	   the	   brain49.	   	   The	   hypothalamus	   (a	  
brain	   region	   that	   regulates	   metabolic	  
processes	  and	  activities	  like	  hunger,	  thirst	  
and	  body	  temperature)	  also	  appears	  to	  be	  
involved,	  especially	  areas	  that	  respond	  to	  
low	   blood	   sugar	   and	   regulate	   energy	  
balance,	   body	   weight	   and	   the	   sensitivity	  
of	  the	  liver	  and	  muscles	  to	  insulin.	  Verbal	  
memory	   also	   appears	   to	   be	   impaired	   in	  
groups	   with	   Type	   2	   Diabetes	   when	  
compared	   with	   non-­‐diabetic	   controls.	  
Other	   cognitive	  domains,	   including	   visuo-­‐
spatial	   memory,	   attention	   and	  
concentration	  and	  frontal	   lobe/	  executive	  
function,	   have	   tended	   to	   be	   less	  
consistently	  affected50.	  
	  
MEASUREMENT	   OF	   COGNITIVE	  
IMPAIRMENT	  
Cognition,	   commonly	   known	   as	   ‘process	  
of	   thought’,	   refers	   to	   an	   information	  
processing	   view	   of	   an	   individual’s	  
psychological	   functions,	   which	   include	  
processes	   such	   as	   memory,	   language,	  
perception	   and	   problem	   solving51,52.	  
Cognitive	  testing	  is	  a	  way	  of	  assessing	  the	  
cognitive	   capabilities	  of	  an	   individual	   and	  
thus	   serves	   as	   a	   tool	   for	   determining	  
neurological	   problems.	   Winblad	   et	   al53	  
stated	   that	   no	   standardized	   assessment	  
exists	   for	   the	   early	   stages	   of	   mild	  
cognitive	   impairment	   which	   arise	   from	  
diabetes.	  The	  need	  for	  repeated	  cognitive	  
testing	   for	   those	   with	   diabetes	   should	  
become	  a	  standard	  part	  of	  the	  evaluation	  
and	   treatment	   part	   of	   diabetes,	   but	   the	  
question	   remains	   which	   tests	   to	   use.	  
There	   exists	   a	   battery	   of	   cognitive	   tests	  
designed	   to	   assess	   different	   areas	   of	  
cognition.	  Some	  commonly	  used	  tests	  are	  
Trail	   Making	   Tests	   (Part	   A	   and	   Part	   B),	  
Mini	  Mental	  Status	  Examination,	  Mini-­‐Cog	  
Test,	  General	  Practitioner’s	  assessment	  of	  
Cognition,	   Digit	   Symbol	   Test,	   Word	   List	  
Fluency	   and	   Word	   List	   Memory	   and	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Montreal	   Cognitive	   Assessment.	   These	  
tests	  assess	  the	  domains	  of	  attention	  and	  
concentration,	   executive	   functions,	  
memory,	   language,	   visuo-­‐constructional	  
skills,	   conceptual	   thinking,	   calculations	  
and	   orientation.	   The	   other	   biomarkers	  
that	   are	   relevant	   in	   diagnosing	  
neurodegenerative	   diseases	   related	   to	  
diabetes	   include	   but	   not	   limited	   to:	   (1)	  
Biomarkers	   of	   glucose	   metabolism:	  
Glycated	  Hemoglobin	  (HbA1c)	  and	  Fasting	  
Blood	   Glucose;	   (2)	   Biomarkers	   of	  
Inflammation:	  Pro-­‐inflammatory	  cytokines	  
like	   Interleukin-­‐1,	   Interleukin-­‐6,	   Tumor	  
Necrosis	   Factor	   Alpha	   and	   acute	   phase	  
proteins	  like	  C-­‐reactive	  protein	  and	  alpha-­‐
antichymotrypsin	   and	   as	   well	   as	  
homocysteine;	   (3)	   Biomarkers	   of	  
Oxidative	   stress:	   Isoprostane;	   	   (4)	  
Biomarkers	   of	   lipoprotein	   metabolism:	  
Apolipoprotein	   E,	   Total	   cholesterol,	   HDL,	  
LDL,	  Triglycerides;	  and	  (5)	  Erythrocyte	  2,3-­‐
diphosphoglycerate	  ,	   Ferritin,	   Uric	   acid,	  
Alanine	   Aminotransferase	   and	   Aspartate	  
Aminotransferase.	  
	  
DRUG	   THERAPY	   AND	   FUNCTIONAL	  
FOODS/SUPPLEMENTS	   MODALITY	   IN	  
THE	   MANAGEMENT	   OF	   COGNITIVE	  
IMPAIRMENT	  IN	  DIABETES	  
The	  work	  of	  Wahlqvist	  et	  al54	   is	   indeed	  of	  
interest	   as	   they	   showed	   that	   the	  
combination	   of	   sulfonylurea	   and	  
metformin	   (but	   not	   either	   one	   alone)	  
significantly	   reduced	   both	   the	   incidence	  
and	   relative	   risk	   for	   affective	   disorder	   in	  
association	   with	   Type	   2	   Diabetes,	  
irrespective	   of	   gender.	   The	   finding	   that	  
the	   incidence	   of	   affective	   disorder	   was	  
lower	   for	   patients	   with	   Type	   2	   Diabetes	  
taking	  sulfonylurea	  and	  metformin	  than	  it	  
was	   for	   their	   peers	  who	  were	   not	   taking	  
these	   agents	   is	   "not	   entirely	  
unexpected,"55	   and	   it	   has	   been	   pointed	  
out	   that	   pioglitazone	   (antihyperglycemic	  
drug)	  also	  has	  antidepressant	  properties.	  
Berr	   et	   al56,	   found	   that	   that	   people	   with	  
low	   cognitive	   functioning	   had	   higher	  
probability	  of	  having	  low	  carotenoid	  levels	  
which	   may	   suggest	   a	   preventive	   role	   for	  
carotenoids	   in	   cognitive	   impairment.	   The	  
antioxidant	   properties	   of	   plant/herbal	  
extracts	  are	  attributed	  to	  the	  presence	  of	  
phenolic	   compounds,	   which	   are	   mostly	  
derivatives,	   and/or	   isomers	   of	   flavones,	  
isoflavones,	   flavonols,	   catechins,	  
tocopherols	   and	   phenolic	   acids.	   These	  
bioactive	   components	   are	   potentially	  
accessible	  to	  consumers	  through	  diet	  and	  
the	   multifunctional	   nature	   of	   these	  
components	   (in	   particular	   flavonoids)	  
makes	   them	   ideal	   candidates	   for	   further	  
investigations	   into	   the	   possible	   beneficial	  
effects	   in	   neurodegenerative	   diseases57.	  
In	   order	   to	   establish	   neuroprotective	  
properties	   of	   antioxidants,	   it	   is	   crucial	   to	  
measure	   ‘markers’	   of	   oxidative	   damage	  
(including	   neuronal	   loss)	   in	   the	   central	  
nervous	   system	   and	   examine	   how	   they	  
are	   affected	  by	  plant/herbal	   extracts	   and	  
dietary	   antioxidants.	   So,	   can	   functional	  
dietary	   supplements	   help	   in	   the	  
management	  of	  diabetes	  and	  also	  reduce	  
the	   risks	   for	   cardiovascular	   disease,	  
neurological	  disease	  and	  other	  conditions	  
worsened	   by	   inflammation	   and	   oxidative	  
stress,	   including	   cognitive	   decline	   and	  
depression?	   The	   question	   that	   needs	   to	  
be	   fully	   addressed	   is	   can	   nutritional	  
antioxidants/nutraceuticals	   and/or	  
dietary	   supplements	   enable	  maintenance	  
of	   integrity	   in	   the	   face	   of	   decreasing	  
cognition	   associated	   with	   diseases	   of	  
overt	   inflammation/neuroinflammation	  
and	  age	  associated	  diseases.	  
	  
CONCLUSION	  
The	  prevalence	  of	   diabetes	   in	   the	  elderly	  
is	  growing	  as	  a	  result	  of	  both	  the	  increase	  
of	   life	   expectancy	   and	   incidence	   of	  
diabetes	   in	   the	   general	   population.	   It	   is	  
understandable	  that	  the	  consequences	  of	  
diabetes	   can	   exacerbate	   degenerative	  
complications	   and	   the	   effects	   of	   co-­‐
morbidities.	   The	   use	   of	   available	  
therapeutic	   drugs	   coupled	   with	  
nutraceutical	   adjuncts	   could	   represent	   a	  
potential	   therapeutic	   strategy	   for	   the	  
reduction	  of	  mental-­‐health	  consequences	  
and	  serve	  as	  a	  preventive	  measure	  for	  at-­‐
risk	   individuals.	   An	   understanding	   of	   the	  
mechanisms	  of	  diabetes-­‐related	  cognitive	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impairment	  and	  the	  resulting	  behaviors	  of	  
patients	  can	  help	  healthcare	  professionals	  
implement	   treatments	   to	   significantly	  
improve	  health	  status	  and	  quality	  of	  life	  of	  
patients	  with	  diabetes.	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